Everest Medicines

Aging Asia And China Will Raise Demand For CAR-T Therapies

AnalystHighTarget

Not Invested

Community Contributor

Published

05 Aug 25

AnalystHighTarget's Fair Value

HK$87.95

37.5% undervalued

10 Sep

HK$54.95

113.4%

-4.9%

113.4%

-4.9%

You can edit this narrative until Aug 5 9:34 PM. Then, changes will post as Updates.

Author's Valuation

HK$87.95

37.5% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

HK$87.95

37.5% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

31.86%

Biotech revenue growth rate

8.19%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.89%

Calculation

CN¥1.12b

Earnings '28

29.50x

PE Ratio '28

CN¥33.08b

Market Cap '28

CN¥33.08b

Market Cap '28

336.84m

No. shares '28

CN¥98.20

Share Price '28

CN¥98.20 Share Price '28

Discounted to 2025 @ 6.89% p.a.

CN¥80.41

Fair Value '25

CN¥80.41 Fair Value '25

Converted to HKD @ 1.0938 CNY/HKD Exchange Rate

HK$87.95

Fair Value '25